MUC16 and ovarian cancer: Integrating serum CA-125 levels with other clinical parameters, imaging modalities, and molecular profiling techniques may enhance the diagnostic sensitivity and specificity of biomarker-based screening strategies, leading to earlier detection and improved outcomes in patients with ovarian cancer [12].